This pathological interaction between the two PPDPs has implications for the identification of new biomarkers for neurodegenerative diseases where, in the case of MSA and PD, we propose using both the SYN and TPPP levels and/or the ratio of SYN to TPPP in the CSF. This evidence concerns the gene TPPP and Parkinson disease.